BURLINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, November 13, 2024, to discuss the financial results for the third quarter 2024 and provide a business update. Participants should dial 1-877-407-9208 (domestic) or 1-201-493-6784 ( ...

scPharmaceuticals, Inc. (SCPH) closed the last trading session at $5.06, gaining 12.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $19.83 indicates a 291.9% upside potential. The mean estimate comprises six short-term price targets with a standard deviation of $2.99. While the lowest estimate of $16 indicates a 216.2% increase from the current price level, the most optimistic a ...

ScPharmaceuticals, Inc. (SCPH) came out with a quarterly loss of $0.44 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.36 per share a year ago. These figures are adjusted for nonrecurring items. A quarter ago, it was expected that this company would post a loss of $0.45 per share when it actually produced a loss of $0.36, delivering a surprise of 20%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. scPharmaceuticals, which belongs to ...

Generated 2Q 2024 net FUROSCIX® revenue of $8.1 million, up 33% sequentially from Q1 Completed financing that extends our cash runway through expected profitability Advanced multiple FUROSCIX growth initiatives including label expansion for heart failure, sNDA submission for CKD, and positive topline pivotal PK data for our Autoinjector Company to host investor conference call and webcast today, Wednesday, August 14th, at 4:30pm ET BURLINGTON, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. ...

BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock at a public offering price of $4.00 per share and, to select investors, in lieu of common stock, pre-funded warrants t ...

scPharmaceuticals received $75 million through a combination of debt and royalty financings at close, with access to an additional $50 million The term loan refinances existing debt principal; lowers coupon, extends interest-only period for four additional years, and lowers minimum cash requirement to $5 million BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the "Company"), a pharmaceutical company focused on developing and commercializing products that have the ...

FUROSCIX is now indicated for the treatment of congestion due to fluid overload in adult patients with chronic heart failure, regardless of New York Heart Association (NYHA) functional class Indication expansion allows for the use of FUROSCIX in NYHA Class IV chronic heart failure patients BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the "Company"), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize t ...

SCP-111 Autoinjector achieved primary pharmacokinetic and secondary pharmacodynamic endpoints The autoinjector is being developed to deliver a subcutaneous injection of furosemide as an alternative option to the FDA approved FUROSCIX on-body infusor presentation Company targeting Supplemental New Drug Application (sNDA) submission to the FDA by year-end 2024 BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the "Company"), a pharmaceutical company focused on develop ...

BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the "Company"), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced a proposed underwritten public offering of shares ("Shares") of its common stock or, in lieu of Shares, pre-funded warrants (the "Pre-Funded Warrants") to purchase Shares (the "Offering"). s ...

Financial Data and Key Metrics Changes - The company reported a net loss of $14.1 million for Q1 2024, compared to a net loss of $11.2 million for Q1 2023 [19] - Product revenues were $6.1 million for Q1 2024, up from $2.1 million in Q1 2023, reflecting a significant increase in demand for FUROSCIX [19] - The gross to net discount during Q1 was 19%, slightly up from 2023, with expectations to reach 30% to 35% by the end of the year [69] Business Line Data and Key Metrics Changes - The average number of doses per prescription filled was 6.1 in Q1 2024, up from 5.9 in Q4 2023 [5] - A total of 17,736 doses were written in Q1 2024, with 8,074 doses filled, impacted by the Change Healthcare cyber-attack [71] - The sales force conducted 2,938 in-services from launch through March 31, 2024, an increase from 2,331 in-services completed as of December 31, 2023 [5] Market Data and Key Metrics Changes - The company is seeing a growing number of providers comfortable prescribing FUROSCIX to heart failure patients during critical intervention windows [2] - Approximately 70% of co-pays for FUROSCIX are $100 or less, moving closer to the goal of 75% or more over time [79] - The company anticipates that cancellation rates will normalize over time, with a current cancellation rate of 19% in Q1 2024 [66] Company Strategy and Development Direction - The company is focused on expanding the indication of FUROSCIX to include Class 4 heart failure patients, with a PDUFA date set for August 2024 [65] - A pivotal PK study for a new low-volume auto injector is underway, which could reduce manufacturing costs and improve treatment flexibility [4] - The company is engaged in a multi-channel marketing campaign to drive brand awareness and adoption of FUROSCIX [18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the continued comfort of treating physicians in prescribing FUROSCIX, despite challenges from the Change Healthcare cyber-attack [58] - The company expects momentum to continue as more physicians gain confidence in prescribing FUROSCIX and as they make progress with payor formularies [58] - Management noted that the transition to a new patient services provider is expected to improve patient and physician experiences [64] Other Important Information - Research and development expenses increased to $2.7 million in Q1 2024 from $2.1 million in Q1 2023, primarily due to device development and clinical study costs [72] - Selling, general, and administrative expenses rose to $17.4 million in Q1 2024 from $10.9 million in Q1 2023, driven by increased employee-related and commercial costs [72] Q&A Session Summary Question: Revenue flat despite increased doses filled - Management explained that the revenue of $6.1 million was flat due to a large order from Kaiser Direct in Q4 that did not count in billed doses but affected net revenue [22] Question: Feedback from doctors on prescribing - Management indicated that there is no significant pushback from doctors, and demand is increasing month over month [74] Question: Plans for Class 4 heart failure education - Management stated that they will educate physicians about the Class 4 indication as soon as approval is received, using both direct and non-direct promotion [27] Question: Impact of Change Healthcare on prescriptions - Management noted that while there was a slight lull in prescriptions during the cyber-attack, overall trends remained positive, with scripts growing towards the end of the quarter [37] Question: Future dosing expectations for Class 4 and CKD - Management anticipates that dosing for Class 4 patients may remain around 6 doses, while CKD patients may have similar dosing to heart failure patients, around 4 to 5 doses [42]